Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957–962.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Anderson A, Oliveria SA, et al. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. J Med Econ. 2018;21(8):745–754.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Foster SA, Comer BS, et al. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization. BMC Dermatol. 2018;18(1):4.
   PubMedGoogle Scholar
• Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–593. e583.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic Burden of Psoriasis in the United States: A Systematic Review. JAMA Dermatol. 2015;151(6):651–658.
   PubMed Web of Science ®Google Scholar
• Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72(6):961–967.e965.
   PubMed Web of Science ®Google Scholar
• Melnikova I. Psoriasis market. Nat Rev Drug Discov. 2009;8(10):767–768.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–780.
   PubMed Web of Science ®Google Scholar
• Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432–1440.
   PubMed Web of Science ®Google Scholar
• Work Productivity and Activity Questionnnaire (WPAI) [Internet]. Reilly Associates. WPAI General Information; [updated 2019 Apr; cited 2019 Jan 17]. Available from: http://www.reillyassociates.net/WPAI_General.html.
   Google Scholar
• Chan B, Hales B, Shear N, et al. Work-Related Lost Productivity and Its Economic Impact on Canadian Patients with Moderate to Severe Psoriasis. J Cutan Med Surg. 2009;13(4):192–197.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Gilloteau I, et al. Higher Psoriasis skin clearance is associated with lower annual indirect costs in the United States: A post hoc analysis from the CLEAR study. JMCP. 2018;24(7):617–622.
   PubMed Web of Science ®Google Scholar
• Warren RB, Halliday A, Graham CN, et al. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018;32(12):2178–2184.
   PubMed Web of Science ®Google Scholar
• Mustonen A, Mattila K, Leino M, et al. Psoriasis causes significant economic burden to patients. Dermatol Ther (Heidelb). 2014;4(1):115–124.
   PubMedGoogle Scholar
• Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs for patients with psoriasis. J Am Acad Dermatol. 2017;76(6):AB16.
   Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
   PubMed Web of Science ®Google Scholar
• Li N, Teeple A, Muser E, et al. Use of the dermatology life quality index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real-world data. Clin Exp Dermatol. 2019; [cited 2019 Dec 18]. [Epub ahead of print]. Available from: https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1111/ced.14142
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Reich K, Foley P, et al. Improvement in patient-reported outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the Phase III VOYAGE 1 and VOYAGE 2 studies. Am J Clin Dermatol. 2019;20(1):155–164.
   PubMed Web of Science ®Google Scholar
• FDA [Internet]. Food and Drug Administration. TREMFYA (guselkumab) Injection; [cited 2019 Mar 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761061Orig1s000TOC.cfm.
   Google Scholar
• Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729.
   PubMed Web of Science ®Google Scholar
• Tang C, Chen S, Qian H, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112–124.
   PubMed Web of Science ®Google Scholar
• BLS.gov [Internet]. Bureau of Labor Statistics. National Occupational Employment and Wage Estimates United States; [cited 2019 Jan 16]. Available from: https://www.bls.gov/oes/current/oes_nat.htm#00-0000.
   Google Scholar
• Queiro R, Tejon P, Alonso S, et al. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology (Oxford). 2014;53(7):1178–1185.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Pike J, et al. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514–521.
   PubMed Web of Science ®Google Scholar